Share Name Share Symbol Market Type Share ISIN Share Description
Rosenblatt Group Plc LSE:RBGP London Ordinary Share GB00BFM6WL52 ORD GBP0.002
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 112.00p 29,550 01:00:00
Bid Price Offer Price High Price Low Price Open Price
110.00p 114.00p 112.00p 112.00p 112.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 12.53 3.04 3.83 29.2 89.7

Rosenblatt (RBGP) Latest News

More Rosenblatt News
Rosenblatt Takeover Rumours

Rosenblatt (RBGP) Share Charts

1 Year Rosenblatt Chart

1 Year Rosenblatt Chart

1 Month Rosenblatt Chart

1 Month Rosenblatt Chart

Intraday Rosenblatt Chart

Intraday Rosenblatt Chart

Rosenblatt (RBGP) Discussions and Chat

Rosenblatt Forums and Chat

Date Time Title Posts
20/5/201915:35Rosenblatt Group Plc126

Add a New Thread

Rosenblatt (RBGP) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-05-24 15:29:46113.505,0005,674.75O
2019-05-24 14:54:47111.002,2392,485.29O
2019-05-24 14:24:43111.001,5001,665.00O
2019-05-24 13:21:54110.881,1771,305.06O
2019-05-24 13:08:43113.304,4134,999.93O
View all Rosenblatt trades in real-time

Rosenblatt (RBGP) Top Chat Posts

Rosenblatt Daily Update: Rosenblatt Group Plc is listed in the Support Services sector of the London Stock Exchange with ticker RBGP. The last closing price for Rosenblatt was 112p.
Rosenblatt Group Plc has a 4 week average price of 87p and a 12 week average price of 76.50p.
The 1 year high share price is 142p while the 1 year low share price is currently 71p.
There are currently 80,092,106 shares in issue and the average daily traded volume is 45,914 shares. The market capitalisation of Rosenblatt Group Plc is £89,703,158.72.
riverman77: I don't think it's independent, so paid for research, but nevertheless it all looks pretty credible and measured. Here is an extract - note the share price was 104p when published so bettdr value now Rosenblatt has reported its maiden results following May’s IPO and subsequent acquisition of the Rosenblatt Solicitors business. The first 8 weeks of trading as a plc have delivered results in-line with our 2018 expectations, driven by a strong delivery in the core Dispute Resolution division. The group has also announced the establishment of a new subsidiary which will act as a litigation funder in its clients’ cases, yielding lucrative funding margins currently paid out to external third parties.  Initial results show a strong start: Rosenblatt has delivered £3.0m (+15.4%) of revenue and £1.0m (+11.6%) of adj EBITDA in its first 8 weeks of trading. Despite the addition of c£0.2m of new plc costs in the period, healthy adj EBITDA margins have been maintained at 33.6%. This reflects both the efficient nature of the cost base in the hourglass model and management’s stringent control of costs. We believe June, along with December, to historically be the company’s strongest months of trading. Valuation: undervaluing a high return model: Rosenblatt currently trades on an ex-cash 2018E* P/E of 12.7x or 10.1x on an EV/EBITDA basis. We consider this to materially undervalue this high margin, cash generative business that is delivering robust growth. We also expect Rosenblatt to reward shareholders with a healthy level of dividend distributions from H2/18E onwards (60%+ payout ratio expected
quepassa: 1. a loss is a loss in my book. pretty pathetic in my opinion that the IPO costs alone knock them into statutory loss. 2. But anyway, for sake of argument, let's take your adjusted pbt figure of £1m against total shares in issue of 80million That equates earnings per share of just 1.25 pence against a current share price of 85p. That means that this share is trading at a Price-Earnings ratio of 68 x (yes SIXTY-EIGHT ) times 3.If we use the statutory loss metrics, then the P-E ratio is negative. Two questions: A). Do you think a P/E ratio of 68x means a share is -cheap, -right or -downright expensive B). If we use the statutory loss figure, we get a NEGATIVE p/e ratio. Do you think that's good? Rosenblatt is not a start-up company where you would in my view expect stratospheric p/e ratios but a well-known and established law firm. Nor is it an embryonic pharma company where you might expect losses in the early years due to R+D. It's been around a long time. Good luck to you but it seems to me that the share remains overpriced in my view. ALL IMO. DYOR. QP
ccurtis1994: Positive results but share price down?
pireric: True, but at least they have some very vague basis for it. Easy to make money when your very presence boosts the share price by 5% and when your sells lead to similar drops. No reason for him not to post trades live, but he doesn't
jonwig: @ John. 2350220 - it took Burford five years before its share price made much headway, and you complain about day one! Don't forget, IPOs are made for the benefit of the sellers, not a bargain for the buyers! @ QuePassa - not often we agree; there are no 'no-brainer' investments, though there are plenty of no-brain investors. I'll follow this as the sector interests me, and how this company unfolds interests me as well.
Rosenblatt share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190525 07:53:11